Leadership Maryland graduates Class of 2018, to include TEDCO’s Marketing VP
Leadership Maryland graduated 50 members of the Class of 2018 who completed the professional development program during its 26th annual graduation ceremony Dec. 4 at the Lord Baltimore Hotel.
Potomac, Maryland-based pre-sale home improvement company Curbio Inc., which recently raised $4 million in new funding, is using the investment to expand outside of the Washington region.
BurnAlong, a TEDCO portfolio company, raises $1.3M seed round, former IKEA executive and Md. investor join board
The startup offering streaming health and fitness classes is expanding in corporate wellness. Former IKEA North America President Pernille Spiers-Lopez and Boulder Ventures' Josh Fidler joined the board.
IBBR investigator to lead $3.9M NIH-funded project to develop next generation HIV-1 immunotherapy agents
IBBR researchers recently received $3.9 million from the National Institutes of Health (NIH) to develop a multi-specific, single agent antibody therapeutic against HIV-1 to block virus infection and to clear the reservoir of HIV-infected cells from the body.
What does Amazon's move mean for Maryland startups?
Amazon’s move to Arlington will drive a demand for talent and help bring more venture capital into a region that has been slowly improving in that area.
TEDCO Builder Fund Recognized through MD Chamber of Commerce
This program will “offer operational guidance and financial support to Maryland startups founded by socially or economically disadvantaged entrepreneurs.”
RackTop Systems and Network Runners to Partner and Exhibit at the 2018 CDCA Defense Summit
RackTop Systems, a leading provider of high-performance Software-Defined Storage embedded with advanced security, encryption and compliance, and Network Runners, a top technology consulting services company that serves the commercial and federal government market spaces, today announced they will be
MII portfolio company Asclepix Therapeutics raised over $5 million in new funding that will assist in development of new treatment for eye diseases that are leading causes of blindness in adults.